Matisyahu Shulman

969 total citations
33 papers, 597 citations indexed

About

Matisyahu Shulman is a scholar working on Public Health, Environmental and Occupational Health, Epidemiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Matisyahu Shulman has authored 33 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Public Health, Environmental and Occupational Health, 18 papers in Epidemiology and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Matisyahu Shulman's work include Opioid Use Disorder Treatment (22 papers), Substance Abuse Treatment and Outcomes (18 papers) and Pain Management and Opioid Use (6 papers). Matisyahu Shulman is often cited by papers focused on Opioid Use Disorder Treatment (22 papers), Substance Abuse Treatment and Outcomes (18 papers) and Pain Management and Opioid Use (6 papers). Matisyahu Shulman collaborates with scholars based in United States, Romania and United Kingdom. Matisyahu Shulman's co-authors include Edward V. Nunes, Peter Manu, Jonathan Wai, Lorena Dima, Marc D. Binder, Davy Vancampfort, Christoph U. Correll, Donna R. Zwas, R K Mallya and Ethan J. Halpern and has published in prestigious journals such as SHILAP Revista de lepidopterología, Anesthesiology and American Journal of Roentgenology.

In The Last Decade

Matisyahu Shulman

32 papers receiving 585 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matisyahu Shulman United States	10	210	164	147	102	81	33	597
Christine Leong Canada	17	192 0.9×	211 1.3×	70 0.5×	84 0.8×	39 0.5×	58	852
Hsing‐Hsia Chen Taiwan	18	136 0.6×	66 0.4×	60 0.4×	185 1.8×	46 0.6×	30	780
John Schmittner United States	14	205 1.0×	61 0.4×	239 1.6×	45 0.4×	62 0.8×	25	687
Anders Leifman Sweden	16	284 1.4×	60 0.4×	460 3.1×	56 0.5×	46 0.6×	24	778
Christina Jensen‐Dahm Denmark	17	138 0.7×	252 1.5×	36 0.2×	127 1.2×	77 1.0×	36	766
Michael E Schatman United States	18	228 1.1×	132 0.8×	69 0.5×	148 1.5×	30 0.4×	94	942
Katharina Beck Switzerland	18	105 0.5×	201 1.2×	115 0.8×	76 0.7×	75 0.9×	54	845
Émilie Jouanjus France	19	389 1.9×	141 0.9×	188 1.3×	87 0.9×	61 0.8×	58	1.1k
Lárus S. Guðmundsson Iceland	14	66 0.3×	323 2.0×	63 0.4×	89 0.9×	58 0.7×	25	545
Aytekin Sır Türkiye	13	69 0.3×	129 0.8×	56 0.4×	43 0.4×	47 0.6×	34	933

Countries citing papers authored by Matisyahu Shulman

Since Specialization

Citations

This map shows the geographic impact of Matisyahu Shulman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matisyahu Shulman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matisyahu Shulman more than expected).

Fields of papers citing papers by Matisyahu Shulman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matisyahu Shulman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matisyahu Shulman. The network helps show where Matisyahu Shulman may publish in the future.

Co-authorship network of co-authors of Matisyahu Shulman

This figure shows the co-authorship network connecting the top 25 collaborators of Matisyahu Shulman. A scholar is included among the top collaborators of Matisyahu Shulman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matisyahu Shulman. Matisyahu Shulman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shulman, Matisyahu, Sarah Meyers-Ohki, Patricia Novo, et al.. (2025). Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD). Contemporary Clinical Trials. 150. 107816–107816.

Ross, Rachael K., Matisyahu Shulman, Edward V. Nunes, et al.. (2024). Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity. JAMA Network Open. 7(10). e2436612–e2436612. 2 indexed citations

Ross, Rachael K., Edward V. Nunes, Matisyahu Shulman, et al.. (2024). Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients. Addiction. 119(11). 1975–1986. 6 indexed citations

Shulman, Matisyahu, Scott E. Provost, Patricia Novo, et al.. (2024). Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial. Contemporary Clinical Trials. 142. 107543–107543. 1 indexed citations

Shulman, Matisyahu, Delia Voronca, Kathryn Hefner, et al.. (2023). Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study. Contemporary Clinical Trials. 128. 107148–107148. 2 indexed citations

Shulman, Matisyahu, Jennifer Scodes, Tse‐Hwei Choo, et al.. (2022). Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone. Substance Use & Misuse. 57(11). 1732–1742. 3 indexed citations

Rudolph, Kara E., Matisyahu Shulman, Marc Fishman, et al.. (2022). Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder. Drug and Alcohol Dependence. 239. 109609–109609. 10 indexed citations

Shulman, Matisyahu, Mei‐Chen Hu, Maria A. Sullivan, et al.. (2022). Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials. Drug and Alcohol Dependence. 233. 109343–109343. 3 indexed citations

Tsui, Judith I., Aimee Campbell, Martina Pavlicová, et al.. (2022). Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone. Drug and Alcohol Dependence. 236. 109469–109469. 3 indexed citations

10.

Rudolph, Kara E., Matisyahu Shulman, Marc Fishman, et al.. (2021). Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse. Addiction. 117(3). 637–645. 7 indexed citations

11.

Murphy, Sean M., Philip J. Jeng, Kathryn E. McCollister, et al.. (2021). Cost‐effectiveness implications of increasing the efficiency of the extended‐release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis. Addiction. 116(12). 3444–3453. 3 indexed citations

12.

Shulman, Matisyahu, Tse-Hwei Choo, Jennifer Scodes, et al.. (2021). Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure. Journal of Substance Abuse Treatment. 124. 108292–108292. 8 indexed citations

13.

Shulman, Matisyahu, Roger D. Weiss, John Rotrosen, et al.. (2021). Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”. Addiction Science & Clinical Practice. 16(1). 15–15. 17 indexed citations

14.

Shulman, Matisyahu, Jonathan Wai, & Edward V. Nunes. (2019). Buprenorphine Treatment for Opioid Use Disorder: An Overview. CNS Drugs. 33(6). 567–580. 118 indexed citations

15.

Shulman, Matisyahu, Aimee Campbell, Martina Pavlicová, et al.. (2018). Cognitive functioning and treatment outcomes in a randomized controlled trial of internet‐delivered drug and alcohol treatment. American Journal on Addictions. 27(6). 509–515. 6 indexed citations

16.

Aharonovich, Efrat, Aimee Campbell, Matisyahu Shulman, et al.. (2017). Neurocognitive Profiling of Adult Treatment Seekers Enrolled in a Clinical Trial of a Web-delivered Intervention for Substance Use Disorders. Journal of Addiction Medicine. 12(2). 99–106. 9 indexed citations

17.

Manu, Peter, Lorena Dima, Matisyahu Shulman, et al.. (2015). Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatrica Scandinavica. 132(2). 97–108. 210 indexed citations

18.

Shulman, Matisyahu, et al.. (2013). Thrombotic complications of treatment with antipsychotic drugs.. PubMed. 104(2). 175–84. 28 indexed citations

19.

Halpern, Ethan J., R K Mallya, Mathew David Sewell, Matisyahu Shulman, & Donna R. Zwas. (2009). Differences in Aortic Valve Area Measured with CT Planimetry and Echocardiography (Continuity Equation) Are Related to Divergent Estimates of Left Ventricular Outflow Tract Area. American Journal of Roentgenology. 192(6). 1668–1673. 54 indexed citations

20.

Shulman, Matisyahu, et al.. (1985). Postthoracotomy Pain and Pulmonary Function Following Epidural and Systemic Morphine. Survey of Anesthesiology. 29(5). 283–283. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact